文献速递白血病造血干细胞移植与细胞治疗

STAT5激活促进早期T细胞前体急性淋巴细胞白血病的进展和化疗耐药

STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2023-01-01

该研究利用Lmo2转基因小鼠模型和患者来源的ETP-ALL异种移植瘤,发现IL-7信号促进白血病前干细胞的扩增和克隆演化,活化STAT5B足以驱动T-ALL发生并促进白血病干细胞的扩增和化疗耐药;药物抑制STAT5可诱导分化、减少白血病负荷并克服化疗耐药。

要点

  • IL-7信号非白血病前干细胞形成所必需,但为其扩增和克隆演化为白血病干细胞所必需
  • 活化STAT5B足以在IL-7R缺陷的Lmo2转基因小鼠中驱动T-ALL发生
  • 匹莫齐特药理学抑制STAT5诱导分化、减少白血病干细胞并增强化疗反应

核心结论

  • STAT5是根除ETP-ALL白血病干细胞的 attractive 治疗靶点。

研究设计与样本

  • 使用Lmo2转基因小鼠模型监测化疗耐药的白血病前干细胞和白血病干细胞。
  • 使用IL-7R缺陷的Lmo2转基因小鼠研究IL-7信号的作用。
  • 构建T细胞特异性、多西环素诱导表达组成性活化STAT5B1∗6突变体的新型转基因小鼠。
  • 使用患者来源的ETP-ALL异种移植瘤评估匹莫齐特的体内效果。

主要发现

  • IL-7信号非白血病前干细胞形成所必需,但为其扩增和克隆演化为白血病干细胞所必需。
  • 活化STAT5B足以在IL-7R缺陷的Lmo2转基因小鼠中导致T-ALL发生。
  • STAT5B1∗6在T细胞中单独表达无效应,但促进Lmo2转基因小鼠中白血病干细胞的扩增和化疗耐药。
  • 匹莫齐特药理学抑制STAT5诱导分化并减少白血病干细胞,同时增强化疗反应。
  • 匹莫齐特显著减少体内白血病负荷并克服患者来源ETP-ALL异种移植瘤的化疗耐药。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Interleukin-7 (IL-7) supports the growth and chemoresistance of T-cell acute lymphoblastic leukemia (T-ALL), particularly the early T-cell precursor subtype (ETP-ALL), which frequently has activating mutations of IL-7 signaling. Signal transducer and activator of transcription (STAT5) is an attractive therapeutic target because it is almost universally activated in ETP-ALL, even in the absence of mutations of upstream activators such as the IL-7 receptor (IL-7R), Janus kinase, and Fms-like tyrosine kinase 3 (FLT3). To examine the role of activated STAT5 in ETP-ALL, we have used a Lmo2-transgenic (Lmo2Tg) mouse model in which we can monitor chemoresistant preleukemia stem cells (pre-LSCs) and leukemia stem cells (LSCs) that drive T-ALL development and relapse following chemotherapy. Using IL-7R-deficient Lmo2Tg mice, we show that IL-7 signaling was not required for the formation of pre-LSCs but essential for their expansion and clonal evolution into LSCs to generate T-ALL. Activated STAT5B was sufficient for the development of T-ALL in IL-7R-deficient Lmo2Tg mice, indicating that inhibition of STAT5 is required to block the supportive signals provided by IL-7. To further understand the role of activated STAT5 in LSCs of ETP-ALL, we developed a new transgenic mouse that enables T-cell specific and doxycycline-inducible expression of the constitutively activated STAT5B1∗6 mutant. Expression of STAT5B1∗6 in T cells had no effect alone but promoted expansion and chemoresistance of LSCs in Lmo2Tg mice. Pharmacologic inhibition of STAT5 with pimozide-induced differentiation and loss of LSCs, while enhancing response to chemotherapy. Furthermore, pimozide significantly reduced leukemia burden in vivo and overcame chemoresistance of patient-derived ETP-ALL xenografts. Overall, our results demonstrate that STAT5 is an attractive therapeutic target for eradicating LSCs in ETP-ALL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Tremblay CS, Saw J, Boyle JA, et al. STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia. Blood. 2023. PMID: 36989489. doi:10.1182/blood.2022016322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。